Single UM171-expanded cord blood transplant can cure severe idiopathic aplastic anemia in absence of suitable donors.
Anemia, Aplastic
/ diagnosis
Cord Blood Stem Cell Transplantation
/ methods
Graft Rejection
Graft Survival
Hematopoietic Stem Cells
/ drug effects
Humans
Indoles
/ pharmacology
Pyrimidines
/ pharmacology
Severity of Illness Index
Tissue Donors
Transplantation Conditioning
/ methods
Transplantation, Homologous
Treatment Outcome
aplastic anemia
cord blood expansion
cord blood transplant
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
05
06
2020
revised:
26
07
2020
accepted:
27
07
2020
pubmed:
5
8
2020
medline:
30
7
2021
entrez:
5
8
2020
Statut:
ppublish
Résumé
Haplo-identical donors have been increasingly used as an alternative source of stem cells in patients with severe aplastic anemia in need of an allogeneic transplantation but lack a matched donor. Single cord blood (CB) transplant also offers a curative option for this disease, but few adult patients have been reported due to low number of progenitor cells leading to prolonged cytopenias and a high risk of infections. CB stem cell expansion may theoretically solve these pitfalls but has not been used previously in non-malignant diseases, likely due to fear of graft rejection and lack of availability of expanded CBs outside clinical trials. We report the first case of an adult patient with severe aplastic anemia who was successfully transplanted with a UM171-expanded CB graft. After a conditioning of rabbit antithymocyte globulin, fludarabine, cyclophosphamide, and total body irradiation, a UM171 expanded graft of 3.29 × 10
Substances chimiques
Indoles
0
Pyrimidines
0
UM171 compound
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
808-811Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Georges GE, Doney K, Storb R. Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment. Blood Adv. 2018;2(15):2020-2028.
Peffault de Latour R, Chevret S, Jubert C, et al. Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study. Blood. 2018;132(7):750-754.
Kiernan J, Damien P, Monaghan M, et al. Clinical studies of ex vivo expansion to accelerate engraftment after umbilical cord blood transplantation: a systematic review. Transfus Med Rev. 2017;31(3):173-182.
Fares I, Chagraoui J, Gareau Y, et al. Cord blood expansion. pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science. 2014;345(6203):1509-1512.
Cohen S, Roy J, Lachance S, et al. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study. Lancet Haematol. 2019;7(2):e134-e145.
Barker JN, Kurtzberg J, Ballen K, et al. Optimal practices in unrelated donor cord blood transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2017;23(6):882-896.
Bejanyan N, Kim S, Hebert KM, et al. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv. 2019;3(20):3123-3131.
Leveson-Gower DB, Sega EI, Kalesnikoff J, et al. Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells. Blood. 2013;122(22):3659-3665.